Heart Failure in Diabetes Mellitus: An Updated Review.
DM
HF
Heart failure
T2DM
diabetes
diabetic cardiomyopathy
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
05
2020
accepted:
12
10
2020
pubmed:
21
11
2020
medline:
27
4
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
Diabetes mellitus (DM) and heart failure (HF) are comorbid conditions associated with significant morbidity and mortality worldwide. Despite the availability of novel and effective therapeutic options and intensive glycaemic control strategies, mortality and hospitalisation rates continue to remain high and the incidence of HF persists. In this review, we described the impact of currently available glucose-lowering therapies in DM with a focus on HF clinical outcomes. Non-conventional modes of management and alternative pathophysiological mechanisms with the potential for therapeutic targeting are also discussed.
Identifiants
pubmed: 33213313
pii: CPD-EPUB-111616
doi: 10.2174/1381612826666201118091659
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5933-5952Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.